- Home
- IGR vs AUTL Comparison
IGR vs AUTL Comparison
Compare IGR & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGR
- AUTL
- Stock Information
- Founded
- IGR 2004
- AUTL 2014
- Country
- IGR United States
- AUTL United Kingdom
- Employees
- IGR N/A
- AUTL N/A
- Industry
- IGR Finance Companies
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IGR Finance
- AUTL Health Care
- Exchange
- IGR Nasdaq
- AUTL Nasdaq
- Market Cap
- IGR 752.8M
- AUTL 625.4M
- IPO Year
- IGR N/A
- AUTL 2018
- Fundamental
- Price
- IGR $4.92
- AUTL $2.49
- Analyst Decision
- IGR
- AUTL Strong Buy
- Analyst Count
- IGR 0
- AUTL 5
- Target Price
- IGR N/A
- AUTL $9.32
- AVG Volume (30 Days)
- IGR 747.7K
- AUTL 1.5M
- Earning Date
- IGR 01-01-0001
- AUTL 08-12-2025
- Dividend Yield
- IGR 13.93%
- AUTL N/A
- EPS Growth
- IGR N/A
- AUTL N/A
- EPS
- IGR N/A
- AUTL N/A
- Revenue
- IGR N/A
- AUTL $9,011,000.00
- Revenue This Year
- IGR N/A
- AUTL $471.17
- Revenue Next Year
- IGR N/A
- AUTL $115.34
- P/E Ratio
- IGR N/A
- AUTL N/A
- Revenue Growth
- IGR N/A
- AUTL N/A
- 52 Week Low
- IGR $3.88
- AUTL $1.11
- 52 Week High
- IGR $5.70
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- IGR 35.64
- AUTL 55.47
- Support Level
- IGR $4.90
- AUTL $2.33
- Resistance Level
- IGR $5.07
- AUTL $2.69
- Average True Range (ATR)
- IGR 0.08
- AUTL 0.16
- MACD
- IGR -0.03
- AUTL -0.02
- Stochastic Oscillator
- IGR 11.84
- AUTL 43.24
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.